Active, not recruitingPHASE2, PHASE3NCT06295731
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inhibrx Biosciences, Inc
- Principal Investigator
- Clinical LeadInhibrx Biosciences, Inc
- Intervention
- INBRX-106(drug)
- Enrollment
- 410 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- City of Hope Medical Center, Duarte, California, United States
- Los Angeles Cancer Network (LACN), Los Angeles, California, United States
- UC Davis, Sacramento, California, United States
- Medical Oncology Associates of San Diego, San Diego, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- ChristianaCare Health Services, Newark, Delaware, United States
- University of Florida UF Health Cancer Center, Gainesville, Florida, United States
- The Oncology Institute of Hope & Innovation, Miami, Florida, United States
- Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
- Cleveland Clinic Florida, The Maroone Cancer Center, Weston, Florida, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Washington University St. Louis, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06295731 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →